Stephen A Sherwin

Director Stephen A Sherwin sold 25,000 NBIX shares for $4.1M via 5 separate transactions on 2026-06-05 under 10b5-1 plan

Stephen A Sherwin, a director at Neurocrine Biosciences, executed 5 separate sales totaling 25,000 shares for $4,132,968.87 at prices ranging from $163.81 to $167.31 on 2026-06-05, reducing his non-derivative holdings from 40,860 shares to 15,860 shares (-61.2%). This transaction was scheduled under a pre-arranged 10b5-1 trading plan adopted on 2026-03-06, meaning it was not discretionary. At the time of the sales, the current stock price of $165.24 was near the blended average transaction price of $165.32 and within 2.6% of the 52-week high of $169.57. The company's fundamentals remain solid with $814.5M in latest quarterly revenue, $197.9M net income, and 21.4% annual revenue growth, though the P/E of 24.85 reflects current market valuation. No derivative securities remain after this filing.

Director Sherwin Stephen A sold 8,760 shares of BIIB at $150.02 for $1,314,141.91; stock down -36.4% from 52-week high, P/E 10.58.

Sherwin Stephen A sold 8,760 shares on 2025-03-07, reducing his holdings by -43.6% from 20,078 to 11,318 shares at a price of $150.02. The stock is currently trading 30-day change: +6.6% and 90-day change: -3.6%, down -36.4% from its 52-week high of $236.80. Across his cross-ticker track record, his prior sells averaged a 90-day return of +14.3%, meaning the stock typically rose after he sold, which reflects poorly-timed exits historically. At the current valuation (P/E 10.58, revenue growth -1.6% annually), the sale occurs with BIIB trading significantly below recent highs and at modest profitability multiples. The substantial reduction in stake (43.6%) warrants observation of whether this reflects portfolio reallocation or changed conviction at BIIB specifically.

Director Stephen Sherwin sold 13,831 shares of NBIX at $116.69 (-56.4% of holdings); stock down -25.0% from 52-week high

Director Stephen Sherwin executed a substantial open-market sale of 13,831 shares (13.8K shares) on 2025-02-13 at $116.69, reducing his NBIX position from 24,504 shares to 10,673 shares (a -56.4% reduction). The sale occurred as the stock trades at $115.02, currently -25.0% below its 52-week high of $153.29 and down -19.3% over the past 30 days. Sherwin's cross-ticker track record shows 2 prior sales with an average 90-day return of +14.3%, indicating his prior NBIX and other-ticker sales were followed by stock appreciation rather than declines. At NBIX specifically, his 2 prior sales (both on 2024-05-29) similarly posted +14.3% 90-day returns, meaning 0 of his prior sales were well-timed at the 90-day mark. The company's fundamentals remain robust: FY revenue growth of +24.8%, a P/E of 24.01, and net income of $129,800,000.00, with latest quarterly revenue of $622,100,000.00. The sale's timing in a period of significant recent price weakness, combined with a track record of prior sales followed by appreciation rather than declines, warrants monitoring to assess whether this transaction signals a shift in outlook or represents a routine portfolio adjustment.